# DESCRIPTION

## STATEMENT REGARDING FEDERALLY FUNDED RESEARCH

- no federally funded research

## BACKGROUND

- introduce CCHF disease
- describe environmental reservoir and vector
- list symptoms of CCHF
- identify high-risk groups
- discuss previous attempts at preventative treatment
- highlight need for new compositions and methods

## SUMMARY

- introduce recombinant vesicular stomatitis virus vectors
- describe Crimean-Congo Hemorrhagic Fever glycoprotein precursor
- outline replication competent ΔGrVSV-CCHFV-GPC
- specify nucleotide sequence identity
- describe single nucleotide polymorphisms
- outline codon optimized CCHFV-GPC
- describe expression vector
- outline replication deficient ΔGrVSV-CCHFV-GPC
- specify nucleotide sequence identity
- describe transcription control systems
- outline chicken actin promoter
- compare nucleotide sequence identities
- describe amino acid sequence identity
- outline expression cassette
- describe plasmid vector
- outline recombinant Vesicular Stomatitis Virus
- describe vaccine composition
- outline methods of producing immune response
- describe administration methods
- outline methods of producing replication competent ΔGrVSV-CCHFV-GPC
- describe passaging VSV glycoprotein complemented recombinant Vesicular Stomatitis Virus
- outline methods of producing replication competent ΔGrVSV-CCHFV-GP
- describe infecting cell culture
- outline kits
- describe methods for identifying subjects infected with Crimean-Congo Hemorrhagic Fever virus
- outline detecting glycoprotein/antibody complexes
- define recombinant vesicular stomatitis virus
- define protein, peptide, polypeptide, and amino acid sequence
- define variant
- define mutant
- define antigen and immunogen
- define nucleotide sequences and nucleic acid sequences
- define transgene and heterologous nucleic acid sequence
- describe codon optimization
- outline functionally and/or antigenically equivalent variants and derivatives
- describe conservative amino acid substitutions
- outline sequence identity determination
- describe algorithm for comparing sequences
- define vector
- outline expression of antigens in vitro and in cultured cells
- describe in vivo expression
- outline regulatory or nucleic acid control sequences
- define promoter
- describe pharmaceutically acceptable compounds and materials

## DESCRIPTION

- introduce CCHFV
- describe CCHFV genome
- explain CCHFV transmission
- discuss CCHFV case-fatality rates
- motivate need for vaccines and therapeutic countermeasures
- describe current experimental vaccine candidates
- discuss limitations of current vaccine candidates
- introduce rVSV as a promising vaccine platform
- motivate use of rVSV for CCHFV
- state aim of the study
- introduce recombinant virus

### I. RECOMBINANT VIRUS

- introduce VSV
- describe VSV structure
- explain VSV replication
- introduce rVSV
- describe rVSV preparation
- introduce ΔGrVSV-CCHFV-GPC
- describe replication competent ΔGrVSV-CCHFV-GPC
- describe replication deficient ΔGrVSV-CCHFV-GPC
- list variant nucleotides
- describe A104 variant
- describe T1615 variant
- describe A1626 variant
- describe additional variants

### II. VACCINES OR IMMUNOGENIC COMPOSITIONS

- introduce vaccines or immunogenic compositions
- describe rVSV-CCHFV-GPC and rVSV-CCHFV-GP
- administer nucleotide sequences and/or antigens in vivo
- define subject
- express transgenes in laboratory animal
- express transgenes in human subjects
- describe immunogenic composition
- summarize nucleotide sequences and/or antigens
- describe genetic vaccines
- list composition forms
- prepare composition
- list carriers and excipients
- describe adjuvants
- list adjuvant examples
- describe controlled-release formulations
- prepare controlled-release formulations
- describe dosage determination
- measure immune response
- administer prophylactically
- administer therapeutically
- describe delivery methods
- describe immunization schedules
- describe prime-boost regimens
- describe DNA prime-boost regimens
- co-administer with other immunogens
- describe kit components

### III. KITS

- describe kit components

### IV. EXAMPLES

- introduce example 1
- describe replication competent vesicular stomatitis vector
- motivate codon optimized CCHFV-GPC
- examine expression of CCHFV-GPC in human liver cells
- describe immunofluorescence staining of CCHFV-GC
- clone and recover ΔGrVSV-CCHFV-GPC
- describe modification of DNA clone recovery system
- use VSV-G complementation to facilitate assembly
- recover virion containing CCHFV-GPC
- passage virus on VSV-G complemented BHK cells
- passage virus on un-complemented BHK cells
- observe cytopathic effect and plaque formations
- harvest RNA and stain for CCHFV-GC antigen
- perform Sanger sequencing of constructs
- perform next generation sequencing
- identify single nucleotide polymorphisms
- analyze growth kinetics of rVSV vectors
- perform single-cycle growth curve analysis
- examine expression of CCHFV-GPC in vitro
- perform immunofluorescence microscopy
- examine incorporation of CCHFV-GC onto virions
- perform Coomassie staining and western blot analysis
- analyze ultrastructure of replication competent recombinant
- perform transmission electron microscopy studies
- examine length of particles
- employ immunolabeling with CCHFV-GC MAb
- design in vivo study to test vaccine
- select STAT-1−/− mouse model for CCHFV
- design pilot study to test conditions and doses
- vaccinate mice with replication deficient construct
- boost mice with replication competent construct
- challenge mice with CCHFV strain IbAr10200
- observe survival rates
- design second experiment to increase prime dose
- challenge mice with CCHFV strain Turkey2004
- analyze humoral response in mice
- examine IgG response to CCHFV-GP
- determine neutralizing capacity of sera
- motivate CCHFV vaccine development
- describe GC tail truncation effect
- discuss localization signal in transmembrane region
- summarize structural GC properties
- explore rVSV vector as vaccine candidate
- discuss murine virulence of rVSV expressing CCHFV-GP
- describe pilot study design and results
- hypothesize time-to-death in STAT-1−/− model
- discuss IbAr10200 strain limitations
- introduce Turkey2004 strain as alternative
- compare genomic analysis of IbAr10200 and Turkey2004
- discuss implications for vaccine design
- present ELISA and PRNT results
- analyze humoral response in prime and boosted groups
- discuss clinical data and tissue analysis
- correlate protection with IgG titers and neutralization
- review existing CCHFV vaccine studies
- discuss limitations of study and future directions
- introduce IS murine model as alternative
- conclude on replication competent construct
- describe cell culture and challenge virus
- detail antibodies used
- generate ΔGrVSV-CCHFV-GPC vectors
- clone and recover rVSV vector
- modify pVSVΔG vector with CCHFV-GPC insert
- transfect and recover VSV-G*-ΔGrVSV-CCHFV-GPC
- store recovered virus for further use
- introduce examples
- infections and enumeration
- growth kinetics
- preparation of viral material
- CCHFV-GC protein analysis
- immunofluorescence analysis
- whole virion analysis
- RNA purification
- cDNA creation
- Sanger sequencing analysis
- deep sequence analysis
- ultrastructural analysis
- ethics of care
- vaccination
- animal challenge
- anti-CCHFV-GPC IgG ELISA development
- ELISA optimization
- plaque reduction neutralization assay
- immunohistochemistry of tissues
- tissue section preparation
- antigen retrieval
- blocking endogenous peroxidase activity
- IHC processing
- detecting specific anti-CCHFV immunoreactivity
- developing slides
- statistical analysis of viral titers
- Kaplan-Meier survival curve analysis

